Printer Friendly
The Free Library
4,484,045 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CRUCELL/US NAVY SIGN PACT TO TEST ADVAC-BASED VACCINE.


Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL), Leiden Leiden or Leyden (both: lī`dən), city (1994 pop. 114,892), South Holland prov., W Netherlands, on the Old Rhine (Oude Rijn) River. Manufactures include medical equipment, machinery, graphic arts, and food products. The famous State Univ. of Leiden is there (founded 1575), the oldest in the Netherlands., The Netherlands, has signed a Cooperative Research and Development Agreement (CRADA CRADA - Cooperative Research And Development Agreement) with the Naval Medical Research Center of the US Navy to construct AdVac-based vaccines against anthrax and plague and test them in non-human primates.

Like Ebola and Marburg Marburg: see Maribor, Slovenia., anthrax and plague are among the so-called 'Category A' agents, which are considered by the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) to pose a significant risk in the event of use as bioterrorist agents. Category A agents can be easily disseminated or transmitted from person-to-person, result in high rates of mortality, may cause public panic and require special action for public health preparedness.

Crucell is already in the course of developing an Ebola vaccine with the Vaccine Research Center (VRC VRC - Fleet Logistics Support Squadron (US Navy designation for naval aviation transport unit)
VRC - Fleet Tactical Support Squadron (US Navy aviation unit designation used from 1960 to 1976)
VRC - Vaccine Research Center (National Institutes of Health)
VRC - Validation Review Committee
VRC - Valve Repair Council
VRC - Variable Rate Coding
VRC - Vehicle Research Center (Insurance Institute for Highway Safety)
VRC - Vehicular Radio Communications
) of the US National Institutes of Health and the US Army Medical Research Institute for Infectious Diseases (USAMRIID USAMRIID - United States Army Medical Research Institute of Infectious Diseases (US DoD)), utilizing adenovirus vector technology and PER.C6 C6 - Communications and Signals Staff production technology. The same technology will be used for the collaboration with the US Navy on anthrax and plague. Under the terms of the CRADA, Crucell has obtained an option on exclusive commercialization rights to any vaccine that could result from the collaboration.

"This program builds directly on our experience with the AdVac and PER.C6 technologies utilized in the HIV programs with Merck, IAVI IAVI - International AIDS Vaccine Initiative and Harvard, our malaria program with NIH and the US Army and the TB program with Aeras," said Crucell's chief scientific officer, Dr. Jaap Goudsmit. "The primate studies are modeled after the Ebola studies we have conducted with the VRC and USAMRIID. We are very proud that AdVac technology is gaining wider acceptance as a system for population-wide vaccination in the area of biodefense."

About Crucell

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies. The company's development programs include collaborations with: sanofi pasteur for influenza vaccines; the U.S. National Institutes of Health National Institutes of Health (NIH), agency of the U.S. Public Health Service, with headquarters in Bethesda, Md. It was established initially in 1887 as a laboratory in the U.S. Marine Hospital on Staten Island in New York City, and was given its present name in 1948. The NIH conducts and supports biomedical research into the causes, cure, and prevention of disease. for Ebola and malaria vaccines; and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its PER.C6 production technology. The company also licenses its PER.C6 technology to the biopharmaceutical industry. Licensees and partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL).

For more information, visit http://www.crucell.com or call 212/926-1733.
COPYRIGHT 2005 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Geographic Code:4EUNE
Date:Oct 1, 2005
Words:429
Previous Article:BIOVITRIM/SANTHERA SIGN PACT FOR DEVELOPING DPP-IV.
Next Article:HEPALIFE COLLABORATES WITH USDA ON LIVER STORAGE RESULTS.
Topics:



Related Articles
Logicon signs pact for near $10 million. (Navy contract)
AERAS/CRUCELL TO DEVELOP TB VACCINE.
CRUCELL LICENSES PER.C6 TECHNOLOGY TO GLAXOSMITHKLINE.
CRUCELL/MERIAL SIGN LICENSE PACT FOR PER.C6 TECHNOLOGY.
CRUCELL/DSM SIGN LICENSING PACT WITH MITSUBISHI PHARMA.
U.S. military bases in Latin America and the Caribbean.
CRUCELL APPOINTS AGENTS TO BOOST ASIAN MARKET POTENTIAL.
US and China work together to combat infectious diseases.(An Advertising Supplement)(Advertisement)
CRUCELL/AERAS START TURBERCULOSIS VACCINE CLINICAL TRIAL.
HPV VACCINE DEBATE HEATS UP.(News)

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles